Treatment of hyperinflammatory syndrome
AssigneeRemicine IP B.V.
InventorDjohan HASAN
Life of this patent
Estimating the term…
Abstract
Described is an antagonist of a mammalian P2X7R for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the said P2X7R antagonist in the said patient to a concentration in the said targeted lymph nodes that is above the maximal tolerable plasma level of the said antagonist in the said mammal.
Claims20
A method for the treatment of a hyperinflammatory syndrome in a mammalian patient, comprising primary lymph node targeted administration of a mammalian P2X7 receptor (P2X7R) antagonist to the said patient to a concentration in the said targeted lymph nodes that is above the maximal tolerable plasma level of the said antagonist in the said mammal.
Dependencies are inferred from the claim text.